Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC15828 AMG232

    2-((3R,5R,6S)-5-(3-氯苯基)-6-(4-氯苯基)-1-((S)-1-(异丙基磺酰基)-3-甲基丁烷-2-基)-3-甲基-2-氧代哌啶-3-基)乙酸,AMG 232;AMG-232

    An inhibitor of the MDM2 and p53 interaction
  3. GC13589 CID 755673 An inhibitor of protein kinase D
  4. GC12332 NU 7026

    2-(4-吗啉基)-4H-萘并[1,2-B]吡喃-4-酮,LY293646

    Inhibitor of DNA-dependent protein kinase
  5. GC15866 Capecitabine

    卡培他滨

    A prodrug of 5-fluorouracil
  6. GC13317 WEHI-539 hydrochloride A selective Bcl-xL inhibitor
  7. GC12391 Xanthohumol

    黄腐醇

    A natural prenylated chalcone

  8. GC10824 DBeQ

    JRF 12

    A selective inhibitor of the ATPase p97
  9. GC10350 TIC10 isomer

    ONC201 isomer

    TIC10异构体是TIC10的异构体。
  10. GC12773 Palomid 529

    P529

    An inhibitor of mTORC1 and mTORC2 formation
  11. GC12337 Tenovin-3

    Tenovin 3;Tenovin3

    A small molecule activator of p53
  12. GC11224 BI6727(Volasertib)

    伏拉塞替; BI 6727

    A polo-like kinase inhibitor
  13. GC16821 TAE226(NVP-TAE226)

    TAE 226;TAE-226

    A dual inhibitor of FAK and IGF-1R
  14. GC15022 Vandetanib (ZD6474)

    凡德他尼; ZD6474

    A multi-kinase inhibitor
  15. GC17648 Dinaciclib(SCH727965)

    (2S)-1-[3-乙基-7-[[(1-氧代-3-吡啶基)甲基]氨基]吡唑并[1,5-A]嘧啶-5-基]-2-哌啶乙醇,SCH 727965

    A CDK inhibitor
  16. GC13070 Cytarabine

    阿糖胞苷; Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C

    Cytarabine(Ara-C)是一种胞嘧啶类似物,主要抑制DNA聚合酶的功能来阻断DNA合成。
  17. GC15739 CHIR-124

    4-[((3S)-1-氮杂双环[2,2,2]辛-3-基)氨基]-3-(1H-苯并咪唑-2-基)-6-氯喹啉-2(1H)-酮

    A selective Chk1 inhibitor
  18. GC13671 Busulfan

    白消安

    An alkylating antineoplastic agent
  19. GC13286 ZM336372 An activator of the Raf-1 signalling pathway
  20. GC13803 Triflurdine (Viroptic)

    曲氟尿苷; Trifluorothymidine; 5-Trifluorothymidine; TFT

    A thymidine analog that inhibits DNA synthesis
  21. GC10978 Terfenadine

    特非那定; (±)-Terfenadine; MDL-991

    A selective histamine H1-receptor antagonist
  22. GC10585 Simvastatin (Zocor)

    辛伐他汀; MK 733

    An HMG-CoA reductase inhibitor
  23. GC12116 Pitavastatin Calcium

    匹伐他汀钙; NK-104 hemicalcium; Pitavastatin hemicalcium

    An HMG-CoA reductase inhibitor
  24. GC17318 Orlistat

    奥利司他; Tetrahydrolipstatin; Ro-18-0647

    奥利司他是胰脏和胃中脂肪酶的不可逆抑制剂,是治疗肥胖症的药物。
  25. GC16145 NVP-BGT226

    NVP-BGT226 maleate

    A dual PI3K and mTOR inhibitor
  26. GC14075 Nocodazole

    诺考达唑

    Nocodazole是一种抗有丝分裂药物,是一种快速可逆的微管聚合抑制剂,在无细胞试验中抑制Abl,Abl(E255K)和Abl(T315I),IC50值分别为0.21μM,0.53μM和0.64μM。
  27. GC16976 Mitotane (Lsodren)

    米托坦; 2,4′-DDD; o,p'-DDD

    An inhibitor of steroidogenesis
  28. GC11762 Meloxicam (Mobic)

    美洛昔康

    A selective COX-2 inhibitor
  29. GC17057 Lithocholic Acid

    石胆酸; 3α-Hydroxy-5β-cholanic acid

    A toxic secondary bile acid
  30. GC10474 Laquinimod (ABR-215062)

    拉喹莫德; ABR-215062

    An immunomodulator
  31. GC17866 INCB28060

    卡马替尼; INC280; INCB28060

    An inhibitor of HGFR (c-Met)
  32. GC16880 Flurbiprofen

    氟比洛芬; dl-Flurbiprofen

    A non-selective COX inhibitor
  33. GC15605 Ezetimibe

    依泽替米贝; SCH 58235

    A cholesterol transport inhibitor
  34. GC13029 AZD2014

    3-[2,4-双((3S)-3-甲基吗啉-4-基)吡啶并[5,6-E]嘧啶-7-基]-N-甲基苯甲酰胺,AZD 2014; AZD-2014

    A potent dual mTORC1/2 inhibitor
  35. GC15055 AZ 628

    AZ-628; AZ628

    A Raf kinase inhibitor
  36. GC11786 Acetylcysteine

    乙酰半胱氨酸; N-Acetylcysteine; N-Acetyl-L-cysteine; NAC

    乙酰半胱氨酸是半胱氨酸的 N-乙酰基衍生物。
  37. GC15281 K-252c

    孢菌素甙元,Staurosporinone

    A cell-permeable PKC inhibitor
  38. GC14256 Tivantinib (ARQ 197)

    (3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮,ARQ-197;ARQ197

    An inhibitor of c-Met
  39. GC10970 WP1130

    WP 1130; WP-1130

    A deubiquitinase inhibitor
  40. GC11908 Cisplatin

    顺铂; cis-Platinum; CDDP; cis-Diaminodichloroplatinum

    顺铂是最好的、最早的基于金属的化疗药物之一,用于治疗广泛的实体癌症,如睾丸癌、卵巢癌、膀胱癌、肺癌、宫颈癌、头颈部肿瘤和胃癌等。
  41. GC10225 Dacomitinib (PF299804, PF299)

    达克替尼; PF-00299804; PF-299804

    A pan-ErbB receptor tyrosine kinase inhibitor
  42. GC15904 PP242

    PP242; PP-242

    Potent inhibitor of mTOR kinase in both mTORC1 and mTORC2
  43. GC15134 Fludarabine Phosphate (Fludara)

    磷酸氟达拉滨; NSC 118218 phosphate

    A prodrug form of fludarabine and 2-fluoro-ara-ATP
  44. GC12573 Temsirolimus

    西罗莫司脂化物,Torisel;CCI-779;CCI 779;CCI779

    A specific inhibitor of mTOR activity
  45. GC15818 RAF265

    CHIR-265;RAF 265;RAF-265;CHIR265

    A B-Raf and VEGFR2 inhibitor
  46. GC15680 Perifosine

    哌立福新; KRX-0401; NSC 639966; D21266

    Perifosine 是 Akt 的抑制剂 。

  47. GC10647 FR 180204

    ERK Inhibitor II

    A potent, cell-permeable inhibitor of ERK1/2
  48. GC16436 Tenovin-6 A small molecule activator of p53
  49. GC12508 Nutlin-3b

    4-[[(4R,5S)-4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-基]羰基]-2-哌嗪酮

    The less active enantiomer of (–)-nutlin-3
  50. GC17785 Macitentan

    马西替坦; ACT-064992

    A dual ETA/ETB receptor antagonist
  51. GC10944 Butein

    紫铆因; 2’,3,4,4’-tetrahydroxy Chalcone

    A plant polyphenol

Items 2251 to 2300 of 2734 total

per page

Set Descending Direction